Systemic lupus erythematosis (SLE) is a heterogenous disease of unknown etiology. It is not uncommon to see pleuropulmonary involvement in isolation or along with the involvement of other organ systems in SLE. Pulmonary manifestations of SLE can involve the pleura, lung parenchyma, airways, pulmonary vasculature, and the respiratory muscles. In this review we discuss two important pulmonary manifestations of SLE: acute lupus pneumonitis and diffuse interstitial lung disease. These two conditions have a major impact on the mortality and morbidity of patients with SLE and it is essential to recognize and treat them appropriately. High-resolution computed tomographic scans of the chest and pulmonary function tests help to establish a diagnosis and aid long-term follow-up of these patients. High-dose corticosteroids are the mainstay of treatment for the two conditions, although other agents such as cyclophosphamide, azathioprine, intravenous gamma globulin, and plasmapheresis have been used with varying degrees of success.
An uncommon but well-recognized manifestation of SLE, ALP can be difficult to differentiate from infectious pneumonia because the clinical presentation may be very similar for both conditions. Two series from the 1970s [1, 2] reported a prevalence of ALP in patients with SLE of 9.3 and 4%, respectively, and two recent series [3•,4•] showed a similar prevalence of 8 and 2%, respectively (Table 1) . In contrast, none of 513 SLE patients in a Danish multi-center study who were followed-up with for 8 years developed ALP [5, 6] . The exact prevalence of ALP is difficult to determine because most of the literature is limited to isolated case reports and retrospective studies of small series of patients.
Most patients who develop ALP are young and have a relatively recent history of SLE. In about 50% of patients with SLE who develop ALP, the pulmonary complication can be the initial manifestation of lupus [7] .
Chronic diffuse interstitial fibrosis and ALP may occur in late-onset SLE. Ikeda et al. report that a 92year-old Japanese man, who presented with epistaxis, respiratory symptoms, and bilateral lung infiltrates, was diagnosed as having SLE on the basis of clinical and laboratory findings. The patient responded to pulse doses of methylprednisolone, but the patient developed CT changes and chronic ILD 1 month later and eventually died as a result of an opportunistic infection [8] . Pulmonary involvement tends to be more common in elderly patients with SLE [9] . Generally, ALP develops during a generalized flare of SLE in such a way that the patient has multi-system involvement including nephritis, arthritis, pericarditis, and pleuritis. Fulminant ALP may occur during pregnancy [10] . The complication presents with abrupt onset of fever, dyspnea, cough with scanty expectoration, hemoptysis, tachypnea, and pleuritic chest pain. Cyanosis and bibasilar rales may be other significant physical signs. Arterial blood gas analysis almost always show hypoxia.
Chest radiographs reveal diffuse acinar infiltrates in almost all cases and pleural effusion in about 50% of patients [7] . Rarely, the initial chest radiograph may be normal or may show nodular shadows. Susanto et al. [11] reported that an SLE patient who presented with a 2-week history of dyspnea, pleuritic chest pain, and a normal chest radiograph and computed tomography (CT) scan had a transbronchial lung biopsy that showed changes of acute alveolitis with focal areas of pneumonitis, alveolar hemorrhage, and capillaritis. A repeat CT scan 5 days after the biopsy showed alveolar interstitial infiltrates. Kawasaki et al. [12] described a 24-year-old female SLE patient whose illness presented initially with fever, dry cough, and arthralgia for 1 month. A chest radiograph and CT scan showed bilateral, multiple nodules and diffuse infiltrates in the lower lung fields.
Clinical and radiographic findings in ALP are nonspecific and may be caused by pulmonary infection, alveolar hemorrhage, and other acute pulmonary processes, such as pulmonary embolism and aspiration. It is critical to exclude these conditions as causes because opportunistic infections are more likely to complicate SLE, especially in patients taking high doses of corticosteroids or cytotoxic agents. Bronchoscopy or openlung biopsy helps to establish the diagnosis if the results of initial work-up, such as blood or sputum cultures, are negative for infection.
Pathology of acute lupus pneumonitis
The pathologic findings of ALP are neither diagnostic nor pathognomonic. Matthay et al. [7] reported different histopathological findings in five patients. An open-lung biopsy in an untreated patient showed diffuse, interstitial lymphocytic infiltrates with prominent lymphoid nodules and organizing bronchiolitis. Autopsy tissue from four patients with ALP showed acute alveolar damage with interstitial edema and hyaline membranes. Acute alveolitis was observed in two cases and widespread arteriolar thrombosis in one case. No evidence of vasculitis was found.
Ooi et al. [13] obtained transbronchial lung biopsy in two of ten SLE patients with persistent respiratory problems. SLE was diagnosed 2 and 5 months before the onset of ALP. The biopsy in one patient showed interstitial pneumonia (IP) with inflammatory cell infiltration of the alveolar septa, pneumocyte hyperplasia, and desquamation of the macrophages into the alveolar space. The other patient showed peribronchial fibrosis. Both patients had friable, swollen, and hyperemic bronchial mucosa. Kawasaki et al. [12] described histopathologic finding of acute IP and arteritis in a patient with ALP.
Electron microscopy and direct immunofluorescence studies have described granular deposits of IgG, C3, and DNA antigen in the alveolar septa [14] . Immunoglobulin and C3 deposits within the nuclei of alveolar lining cells and pleural mesothelial cells were described by Pertschuk et al. [15] . The immunopathological findings suggest that the deposition of immune complexes, including IgG anti-ds DNA and DNA antigen, and activation of the complement cascade may play a role in the pathogenesis of ALP [16] . (8) 2 (2) Patients with chronic ILD, n(%) 9 (6) 18 (100) 0 (0) 42 (8) n/a 3(3)
Comments
Nine patients had evidence of pulmonary fibrosis on chest radiograph; no PFTs done Patients enrolled on basis of diffuse interstitial lung infiltrates, also noted to have a restrictive pattern on PFTs; prevalence of ILD was calculated to be ~3% of patients with SLE 38% patients had abnormal chest radiograph; diffuse interstitial infiltrates not noted Prevalence of ILD increased with duration of disease Attempted to establish association between pulmonary complications and other laboratory and clinical features of SLE Clinical features of SLE in patients not specified Table 1 
. Frequency of acute lupus pneumonitis and chronic interstitial lung disease in selected systemic lupus erythematosus series
Boulware and Hedgpeth [17] first reported an association between ALP and anti-Ro/SSa antibodies. Of 16 SLE patients with pulmonary complications, 13 (81%) tested positive for anti-Ro/SSa antibodies (6 had ALP and 9 had chronic ILD). In contrast, anti-Ro/SSa antibodies were found in 24 of 63 (38%) of their entire SLE study group. A recent retrospective analysis of 137 Japanese SLE patients by Mochizuki et al. [3•] confirmed the association between ALP and anti-Ro/SSa antibodies. Anti-Ro/SSA antibodies were found in 9 of 11 (82%) patients with IP and in 54 of 126 (43%) SLE patients without IP. The high frequency of anti-Ro/SSA antibodies raises the possibility that these autoantibodies may be involved in the pathogenesis of ALP. Anti-Ro/SSA antibodies, like anti-ds DNA antibodies, may be deposited as immune complexes or the inflammatory process may induce alveolar cells to express the Ro/SSA antigen on their surface, a phenomenon that has been reported in keratinocytes after ultraviolet (UV) irradiation [18] . Circulating anti-Ro/SSa antibodies can bind to the surface antigens on the alveolar lining cells, activate complement, and induce an inflammatory process.
The association between anti-Ro/SSA antibodies and ALP has not been observed by other investigators. Groen et al. [19] identified a subset of SLE patients with ILD characterized by scleroderma traits and high frequency of anti-U1RNP but not anti-Ro/SSa antibodies.
Tamura et al. [20] described unknown type C retroviral particles in the bronchoalveolar lavage (BAL) cells in a SLE patient with IP. Serum antibodies to this putative type C retrovirus was found in 24% of SLE patients, 27% of patients with idiopathic fibrosis, 0% of patients with lung cancer, and 2% of healthy individuals. The significance of this finding in the pathogenesis of IP is unclear.
Treatment and prognosis
High-dose corticosteroids are the mainstay of ALP treatment. There have not been any controlled studies to determine the efficacy of corticosteroids, immunosuppressive agents, or other drug regimens in the treatment of ALP. Current recommendations are based on clinical experience. The initial therapy for an SLE patient with acute onset of fever, cough, and pulmonary infiltrates includes the use of broad-spectrum antibiotics and supportive care until an infection is excluded. Methylprednisolone is given at an equivalent prednisone dose (1-2mg/kg/day) in divided doses, and "pulse" methylprednisolone is given for critically ill patients (1g IV daily for 3-5 days). In severe and steroid-resistant cases of ALP other agents, including azathioprine, cyclophosphamide, intravenous gamma globulin, and plasmapheresis, have been tried alone or in combination with varying degrees of success [7,21-23].
The prognosis of patients with ALP is poor. In a 1974 series reported by Matthay et al. [7] , six of twelve patients died during the acute episode from respiratory failure, opportunistic infection, and thromboembolism. Of the remaining six patients, three later developed chronic ILD. The factors which contributed to poor outcome included intercurrent infection, aspiration, diaphragmatic dysfunction, cardiac and renal failure, and drug and oxygen toxicity [7] . Boulware and Hedgpeth [17] reported that four of their seven ALP patients died, despite the use of aggressive supportive therapy, corticosteroids, and immunosuppressive therapy. The remaining three patients eventually developed chronic IP. [25] studied the long-term clinical course of some of these patients.
Chronic diffuse interstitial lung disease
The clinical and radiographic features of SLE-associated chronic ILD are similar to that of the idiopathic form of ILD, but the disease course is less severe in the former [25] [26] [27] .
Clinical presentation
Chronic ILD in SLE may present either as a sequelae of ALP as reported by Matthay et al. [7] and Boulware and Hedgpeth [17] or may have a more insidious onset [24, 25] .
The prevalence of symptomatic ILD has been reported to be 3% A recent prospective multi-center study of 513 SLE patients [5,6] showed a progressive increase in prevalence with disease duration. ILD was found in 7 (1%) patients at the onset of the disease, 20 (4%) within 1 year from diagnosis, and 42 (8%) by the end of 12 years. ILD tended to be more common in older patients, men, and patients with late-onset SLE. Pulmonary fibrosis affected 18 of 103 (18%) of patients above the age of 50 years, 12 of 354 (7%) of patients between the ages of 18 and 49 years, and 1 of 56 (2%) of patients under 18 years. The prevalence in men was 14% (8 of 59) and in women was 7.5% (34 of 354). The mean age of patients in the series by Weinrib et al. [25] and Eisenberg et al. [24] were 49.8 and 45.7 years respectively and the duration of the disease was 12 and 10 years respectively.
The clinical manifestations of chronic ILD in SLE are similar to those in other diffuse connective tissue diseases. Persistent exertional dyspnea, pleuritic chest pain, non-productive cough are the most common. Physical examination may show fever, cyanosis, bibasilar crackles. Clubbing is less common in SLE than in idiopathic ILD [28] .
High resolution chest computed tomography in systemic lupus erythematosis
A cross-sectional study of 34 SLE patients by Fenlon et al. [29] correlated HRCT findings with clinical features, chest radiographs, and pulmonary function tests (PFTs). Of the 34 patients, 19 (56%) never smoked and 26 (77%) had no respiratory complaints at the time of the study. Most patients were receiving a combination of medications. Twenty-four (70%) showed HRCT abnormalities, 8 (24%) had abnormal chest radiographs, 14 (41%) had abnormal PFTs, and 11 (33%) were judged to have ILD on the HRCT. No correlation was found between abnormal HRCT and chest symptoms, disease activity, smoking history, and drug therapy. The PFT findings did not correlate with the presence or severity of ILD and bronchiectasis in the HRCT. This study showed a high frequency of airways disease and ILD diagnosed by HRCT despite the absence of symptoms. The clinical significance of these findings is unclear and the correlations need further examination in a prospective longitudinal study.
Bankier et al. [30] evaluated HRCT in a prospective study that included 48 SLE patients who did not have a history of smoking or prior clinical evidence of pulmonary involvement. Of the 45 (94%) patients with normal chest radiographs, 17 (38%) had abnormal HRCT findings including interlobular and intralobular septal thickening, air-space nodules, and architectural distortion. A correlation was found between the extent of the disease at CT with the duration of clinical history and decreased carbon monoxide diffusion capacity (DLCO), forced expiratory volume (FEV1), and forced vital capacity (FVC). The mean duration of the disease was 28.3 months, suggesting that lung changes occur early in the course of SLE. This study is limited in that there is a lack of histopathological study or BAL fluid findings to determine whether the morphologic abnormalities seen in CT represent specific pathologic processes in the lungs.
Sant et al.
[31] studied 29 SLE patients, 11 smokers and 4 ex-smokers. At the time of the study, 6 had respiratory symptoms. In contrast to the study of Bankier et al. [30] , the duration of the SLE was longer (mean = 5.4 years). Abnormal HRCT findings were seen in 20 (72%), which included changes of ILD in 11 patients, and 10 (35%) had abnormal chest radiographs. Of the 15 (52%) asymp-tomatic patients with normal chest radiographs and PFT, 4 (26%) had abnormal HRCT. There was no correlation between abnormal HRCT findings and disease activity and duration, PFT, anti-DNA, and smoking history. This study confirms the high frequency of abnormalities in HRCT.
In contrast to the above studies, Ooi et al.
[13] evaluated HRCT results for 10 SLE patients who had persistent shortness of breath, cough, and pleuritic chest pain, 9 of whom were life-long nonsmokers. The mean duration of SLE was 7.5 years. Abnormal chest radiographs were found in 73% and 3 patients had histological evidence of ILD or IP. Fourteen of 15 (93%) HRCT scans were abnormal and 9 (60%) showed evidence of chronic ILD, predominantly in the lower zones. All 10 patients had abnormal PFT and 6 (60%) had reduced DLCO. The presence of honeycombing and ground glass opacification in the HRCT scans correlated with reduced DLCO. Although abnormal chest radiographs were seen in 7 of the 9 (73%) nonsmoking patients, the abnormalities did not reflect the severity of lung changes seen in the HRCT scans. This study illustrated the high frequency of HRCT abnormalities in SLE patients with persistent overt respiratory complaints.
Serial studies using HRCT to look at SLE, especially in those patients without respiratory symptoms, and correlation with BAL fluid findings are needed to determine whether the CT abnormalities are clinically significant.
A recent prospective study of 59 patients with newonset untreated nonspecific ILD, including 2 (3%) with collagen vascular disease, showed a high rate of diagnostic specificity for idiopathic pulmonary fibrosis based on a thorough clinical assessment (90%) and on radiographic and HRCT results (97%) [32] . However, the sensitivity of these methods is low (62 and 78.5%, respectively) such that the diagnosis was missed for nearly one third of patients despite evaluation by experts in a medical center that is recognized for their experience in treating ILD. The study concluded that open-lung biopsy is not necessary in all patients with typical clinical features of ILD but should be undertaken to diagnose new cases when the transbronchial lung biopsy is nondiagnostic and the clinician is unable to make a diagnosis.
There is insufficient data at this time to make a case for using HRCT finding of ILD as a basis for treatment in an asymptomatic SLE patient. Nevertheless, HRCT can be an excellent laboratory test in symptomatic patients to determine prognosis, based on the severity and extent of acute inflammation versus endstage pulmonary fibrosis, and appropriate therapy.
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) is considered to be an effective and relatively safe method of obtaining inflammatory cells and secretions in patients with pulmonary disease. Analysis of BAL fluid cells in SLE patients without respiratory complaints have shown changes of abnormal BAL (subclinical alveolitis) [33, 34] .
Chhajed et al. [35] analyzed the BAL fluid in untreated, newly diagnosed, and nonsmoking patients with SLE and RA. The mean percentages of lymphocytes, neutrophils, and macrophages were 23.6, 6.2, and 70.5% respectively. There was no difference in the BAL cell distribution in RA and SLE patients. Patients with pulmonary symptoms had a lymphocyte predominance while in those with radiographic changes of ILD there was lymphocyte and neutrophil predominance.
Prospective longitudinal studies are needed in SLE and in other connective tissue diseases to determine whether patients without respiratory symptoms but with an abnormal BAL (subclinical alveolitis) will develop florid ILD.
Treatment and prognosis
There are no controlled prospective studies that look into the efficacy of corticosteroids and other agents used in the treatment of SLE-associated ILD. Most of what is known is based on small case studies and retrospective analysis of series of patients.
Schnabel et al. [36] treated six patients with rapidly progressive ILD associated with collagen vascular diseases. One of the patients had SLE, two had systemic sclerosis, two had polymyositis, and one patient had primary Sjøgren syndrome. All patients received 6 to 9 cycles of intravenous cyclophosphamide at a dose of 0.5g per square meter of body surface together with an initial course of 50mg of prednisolone. All patients responded with significant exercise tolerance and a drop in neutrophils in the BAL fluid, and there was an improvement in the HRCT in four patients. The prednisone dosage was gradually reduced and hydroxychloroquine, azathioprine, and/or cyclosporine were added as maintenance therapy. All patients had stable pulmonary function over a short follow-up study period of 4 to 12 months.
Weinrib et al. [25] followed-up with a group of 14 patients with SLE who had complained of chronic dyspnea on exertion, pleuritic chest pain, and chronic cough (mean = 7.3 years). The majority of the patients had decreased DLCO with a mean of 57% of the predicted value. All of the patients received high doses of corticosteroids (60mg prednisone daily) for 4 weeks early on the course of the clinical pulmonary disease. In most of the patients the DLCO and inspiratory FVC either improved or remained stable and all patients reported subjective improvement in their respiratory symptoms. The study suggests that the clinical course of ILD in SLE is variable but generally follows a slow course and patients tend to improve or stabilize over a period of time. This is in contrast to patients with idiopathic pulmonary fibrosis who deteriorate faster with regards to lung function, develop further restrictive impairment and poorer gas exchange, and have decreased survival rate [28, 37] .
